In the last year, when viewed on a micro-economic scale, it is clear that Chinese pharma is increasingly supporting the entire pharmaceutical value chain, with biopharma in particular seeing government support and investment. The government’s ‘Made in China 2025’ plan listed biomedicine including gene therapies, monoclonal antibodies, and vaccines as the priority for the industry…